Blood Group Genotyping for Sickle Cell and Thalassaemia
- NHS England
Procurement identifier (OCID): ocds-h6vhtk-05f01d
Description
Embedding blood group genotyping into routine practice. The primary objective (benefit) of doing so is to ensure patients with rare blood disorders have a minimise risk of adverse reactions through access to blood group genotyping
Notices
UK6: Contract award notice
- Notice identifier
- 2025/S 000-080350
- Published
- 5 December 2025, 4:50pm
UK5: Transparency notice
- Notice identifier
- 2025/S 000-080318
- Published
- 5 December 2025, 4:13pm